Fundraising Fox

Cambridge Epigenetix

Cambridge · Founded 2012 · United Kingdom corporation · 89 employees on LinkedIn · 8 known investors

Find your way into Cambridge Epigenetix

462 people in our graph share verified history with the Cambridge Epigenetix team — schools, employers, funds. One of them is your warm intro.

Hannah Sealunlockedknows Jason Mellad · together at University of Cambridge (overlapped)
×8knows the team · via University of Cambridge
×3knows the team · via Tulane University

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.

BiotechDeep TechHealthtech

Founders & leadership

JMJason Mellad
Jason MelladinExecutive
MM
Martin MurphyNamed on SEC filing
BY
Bobby Yerramilli-RaoNamed on SEC filing
SS
Somasundaram SubramaniamNamed on SEC filing
TR
Timothy RinkNamed on SEC filing
TH
Thomas HulmeNamed on SEC filing

Board

AN
Alice Newcombe-EllisinBoard directorGeneral Partner at Ahren
SB
Shankar BalasubramanianBoard directorPartner at Ahren Innovation Capital

Investors · 8

Third Point VenturesMenlo Park
AhrenreportedCambridge
Ahren Innovation Capitalreported · 2 sourcesCambridge, Cambridgeshirevia Alice Newcombe-Ellis · board
GV (Google Ventures)reported · 2 sourcesMountain View · $250K – $50M
New Science Venturesreported · 2 sourcesGreenwich · $2M – $8M
Sequoia Capitalreported · 2 sourcesMenlo Park · $4.4M – $214M
TemasekreportedSingapore
Third PointreportedNew York

Funding

SEC filings, press & company announcements

$100.3M disclosed across 2 rounds · 2018–2021

▶$12.3MraisedMay 2018 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin MurphyDirector
  • Jason MelladExecutive Officer, Director
  • Bobby Yerramilli-RaoDirector
  • Alice Newcombe-EllisDirector
  • Somasundaram SubramaniamDirector
  • Timothy RinkDirector
  • Thomas HulmeDirector
  • Shankar BalasubramanianDirector
Offering amount
$12.3M
Amount sold
$12.3M
First sale
Apr 2018
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Cambridge Epigenetix Raises $88M in Series D Funding Round | GenomeWebgenomeweb.com · Nov 2021Cambridge Epigenetix Raises $88 Million Series D Financing to Advance Best-in-Class DNA Sequencing Technology Platformglobenewswire.com · Nov 2021Ahren Leads $30mn Funding Round in Cambridge Epigenetix - Ahren Innovationahreninnovationcapital.com · Apr 2018Google backs Cambridge epigenetics spinoff in a $21M round | Fierce Biotechfiercebiotech.com · Mar 2016Cambridge Epigenetix announces $21M financing round led by Google – Cambridge Enterpriseenterprise.cam.ac.uk · Mar 2016Cambridge Epigenetix raises $5.5M – Cambridge Enterpriseenterprise.cam.ac.uk · Oct 2014

Frequently asked questions

What does Cambridge Epigenetix do?
The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.
Who are Cambridge Epigenetix's investors?
Cambridge Epigenetix's investors include Third Point Ventures, Ahren, Ahren Innovation Capital, GV (Google Ventures), New Science Ventures, Sequoia Capital, Temasek, Third Point.
How much funding has Cambridge Epigenetix raised?
Cambridge Epigenetix has disclosed $100.3M raised across 2 rounds.
Where is Cambridge Epigenetix headquartered?
Cambridge Epigenetix is headquartered in Cambridge.